SpringerLink
Log in

Pharmacokinetics of intravenous mycophenolate mofetil in allogeneic hematopoietic stem cell-transplanted Japanese patients

  • Original Article
  • Published:
Cancer Chemotherapy and Pharmacology Aims and scope Submit manuscript

Abstract

Purpose

Mycophenolate mofetil (MMF) is increasingly used among Japanese patients undergoing allogeneic hematopoietic stem cell transplantation (allo-SCT). Because pharmacokinetic data for MMF in the Asian population are limited, we conducted this investigation.

Methods

Intravenous MMF (1000 mg/dose) was administered to 10 patients along with cyclosporine or tacrolimus for 10 days after allo-SCT; it was administered every 8 h in peripheral blood stem cell- and bone marrow-transplanted patients, and every 12 h in cord blood-transplanted patients. MMF was administered orally at the same dose from day 11. Plasma concentrations of mycophenolic acid (MPA) were measured by high-performance liquid chromatography.

Results

The MPA AUC0 − tau was 31.9 ± 3.4, 26.2 ± 2.4, and 21.0 ± 2.2 µg*h/mL, the mean Ctrough was 0.25, 0.35, and 0.37 µg/mL, and the Cmax was 10.8, 9.2, and 5.5 µg/mL on days 2, 9, and 16, respectively. The AUC0 − tau and Cmax were significantly higher after intravenous MMF dosing than after oral MMF dosing. All patients exhibited successful neutrophil engraftments in a median time of 18 days. Grade II acute graft-versus-host disease (GvHD) of the skin was observed in two patients, and one patient developed limited chronic GvHD. Individual cases of transient and curable grade III oral mucositis and diarrhea were observed; however, MMF was not discontinued. No other severe complications or infections were observed.

Conclusions

Intravenously administered MMF was safe and possibly effective in achieving higher MPA plasma concentrations for GvHD prophylaxis after allo-SCT in Japanese patients.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Subscribe and save

Springer+ Basic
EUR 32.99 /Month
  • Get 10 units per month
  • Download Article/Chapter or Ebook
  • 1 Unit = 1 Article or 1 Chapter
  • Cancel anytime
Subscribe now

Buy Now

Price includes VAT (Thailand)

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2

Similar content being viewed by others

References

  1. Ferrara JL, Levy R, Chao NJ (1999) Pathophysiologic mechanisms of acute graft-vs.-host disease. Biol Blood Marrow Transplant 5(6):347–356

    Article  CAS  PubMed  Google Scholar 

  2. Ruutu T, van Biezen A, Hertenstein B, Henseler A, Garderet L, Passweg J, Mohty M, Sureda A, Niederwieser D, Gratwohl A, de Witte T (2012) Prophylaxis and treatment of GVHD after allogeneic haematopoietic SCT: a survey of centre strategies by the European Group for Blood and Marrow Transplantation. Bone Marrow Transplant 47(11):1459–1464. https://doi.org/10.1038/bmt.2012.45

    Article  CAS  PubMed  Google Scholar 

  3. Ratanatharathorn V, Nash RA, Przepiorka D, Devine SM, Klein JL, Weisdorf D, Fay JW, Nademanee A, Antin JH, Christiansen NP, van der Jagt R, Herzig RH, Litzow MR, Wolff SN, Longo WL, Petersen FB, Karanes C, Avalos B, Storb R, Buell DN, Maher RM, Fitzsimmons WE, Wingard JR (1998) Phase III study comparing methotrexate and tacrolimus (prograf, FK506) with methotrexate and cyclosporine for graft-versus-host disease prophylaxis after HLA-identical sibling bone marrow transplantation. Blood 92(7):2303–2314

    CAS  PubMed  Google Scholar 

  4. Bolwell B, Sobecks R, Pohlman B, Andresen S, Rybicki L, Kuczkowski E, Kalaycio M (2004) A prospective randomized trial comparing cyclosporine and short course methotrexate with cyclosporine and mycophenolate mofetil for GVHD prophylaxis in myeloablative allogeneic bone marrow transplantation. Bone Marrow Transplant 34(7):621–625. https://doi.org/10.1038/sj.bmt.1704647

    Article  CAS  PubMed  Google Scholar 

  5. Haentzschel I, Freiberg-Richter J, Platzbecker U, Kiani A, Schetelig J, Illmer T, Ehninger G, Schleyer E, Bornhauser M (2008) Targeting mycophenolate mofetil for graft-versus-host disease prophylaxis after allogeneic blood stem cell transplantation. Bone Marrow Transplant 42(2):113–120. https://doi.org/10.1038/bmt.2008.85

    Article  CAS  PubMed  Google Scholar 

  6. Basara N, Blau WI, Romer E, Rudolphi M, Bischoff M, Kirsten D, Sanchez H, Gunzelmann S, Fauser AA (1998) Mycophenolate mofetil for the treatment of acute and chronic GVHD in bone marrow transplant patients. Bone Marrow Transplant 22(1):61–65

    Article  CAS  PubMed  Google Scholar 

  7. Bullingham RE, Nicholls AJ, Kamm BR (1998) Clinical pharmacokinetics of mycophenolate mofetil. Clin Pharmacokinet 34(6):429–455. https://doi.org/10.2165/00003088-199834060-00002

    Article  CAS  PubMed  Google Scholar 

  8. Bornhauser M, Schuler U, Porksen G, Naumann R, Geissler G, Thiede C, Schwerdtfeger R, Ehninger G, Thiede HM (1999) Mycophenolate mofetil and cyclosporine as graft-versus-host disease prophylaxis after allogeneic blood stem cell transplantation. Transplantation 67(4):499–504

    Article  CAS  PubMed  Google Scholar 

  9. Dvorak CC, Callard E, Agarwal R (2006) Use of intravenous mycophenolate mofetil for graft-versus-host disease prophylaxis in an allogeneic hematopoietic stem cell transplant recipient with an allergic reaction to cyclosporine and tacrolimus. Bone Marrow Transplant 38(3):253–254. https://doi.org/10.1038/sj.bmt.1705422

    Article  CAS  PubMed  Google Scholar 

  10. Mohty M, de Lavallade H, Faucher C, Bilger K, Vey N, Stoppa AM, Gravis G, Coso D, Viens P, Gastaut JA, Blaise D (2004) Mycophenolate mofetil and cyclosporine for graft-versus-host disease prophylaxis following reduced intensity conditioning allogeneic stem cell transplantation. Bone Marrow Transplant 34(6):527–530. https://doi.org/10.1038/sj.bmt.1704640

    Article  CAS  PubMed  Google Scholar 

  11. Perkins J, Field T, Kim J, Kharfan-Dabaja MA, Fernandez H, Ayala E, Perez L, Xu M, Alsina M, Ochoa L, Sullivan D, Janssen W, Anasetti C (2010) A randomized phase II trial comparing tacrolimus and mycophenolate mofetil to tacrolimus and methotrexate for acute graft-versus-host disease prophylaxis. Biology of Blood Marrow Transplant 16(7):937–947. https://doi.org/10.1016/j.bbmt.2010.01.010

    Article  CAS  Google Scholar 

  12. Al-Kadhimi Z, Gul Z, Chen W, Smith D, Abidi M, Deol A, Ayash L, Lum L, Waller EK, Ratanatharathorn V, Uberti J (2014) High incidence of severe acute graft-versus-host disease with tacrolimus and mycophenolate mofetil in a large cohort of related and unrelated allogeneic transplantation patients. Biology of Blood Marrow Transplant 20(7):979–985. https://doi.org/10.1016/j.bbmt.2014.03.016

    Article  CAS  Google Scholar 

  13. Nakane T, Nakamae H, Yamaguchi T, Kurosawa S, Okamura A, Hidaka M, Fuji S, Kohno A, Saito T, Aoyama Y, Hatanaka K, Katayama Y, Yakushi** K, Matsui T, Yamamori M, Takami A, Hino M, Fukuda T (2017) Use of mycophenolate mofetil and a calcineurin inhibitor in allogeneic hematopoietic stem-cell transplantation from HLA-matched siblings or unrelated volunteer donors: Japanese multicenter phase II trials. Int J Hematol 105(4):485–496. https://doi.org/10.1007/s12185-016-2154-4

    Article  CAS  PubMed  Google Scholar 

  14. Nash RA, Johnston L, Parker P, McCune JS, Storer B, Slattery JT, Furlong T, Anasetti C, Appelbaum FR, Lloid ME, Deeg HJ, Kiem HP, Martin PJ, Schubert MM, Witherspoon RP, Forman SJ, Blume KG, Storb R (2005) A phase I/II study of mycophenolate mofetil in combination with cyclosporine for prophylaxis of acute graft-versus-host disease after myeloablative conditioning and allogeneic hematopoietic cell transplantation. Biol Blood Marrow Transplant 11(7):495–505. https://doi.org/10.1016/j.bbmt.2005.03.006

    Article  CAS  PubMed  Google Scholar 

  15. Neumann F, Graef T, Tapprich C, Vaupel M, Steidl U, Germing U, Fenk R, Hinke A, Haas R, Kobbe G (2005) Cyclosporine A and mycophenolate mofetil vs cyclosporine A and methotrexate for graft-versus-host disease prophylaxis after stem cell transplantation from HLA-identical siblings. Bone Marrow Transplant 35(11):1089–1093. https://doi.org/10.1038/sj.bmt.1704956

    Article  CAS  PubMed  Google Scholar 

  16. Nieto Y, Patton N, Hawkins T, Spearing R, Bearman SI, Jones RB, Shpall EJ, Rabinovitch R, Zeng C, Baron A, McSweeney PA (2006) Tacrolimus and mycophenolate mofetil after nonmyeloablative matched-sibling donor allogeneic stem-cell transplantations conditioned with fludarabine and low-dose total body irradiation. Biology Blood Marrow Transplant 12(2):217–225. https://doi.org/10.1016/j.bbmt.2005.10.012

    Article  CAS  Google Scholar 

  17. Ostronoff F, Ostronoff M, Souto-Maior AP, Domingues M, Sucupira A, Manso DA, de Lima AK, Monteiro PG, Florencio R, Calixto R (2009) Prospective trial of mycophenolate mofetil-cyclosporine A prophylaxis for acute GVHD after G-CSF stimulated allogeneic bone marrow transplantation with HLA-identical sibling donors in patients with severe aplastic anemia and hematological malignancies. Clin Transplant 23(1):33–38. https://doi.org/10.1111/j.1399-0012.2008.00894.x

    Article  PubMed  Google Scholar 

  18. Sabry W, Le Blanc R, Labbe AC, Sauvageau G, Couban S, Kiss T, Busque L, Cohen S, Lachance S, Roy DC, Roy J (2009) Graft-versus-host disease prophylaxis with tacrolimus and mycophenolate mofetil in HLA-matched nonmyeloablative transplant recipients is associated with very low incidence of GVHD and nonrelapse mortality. Biol Blood Marrow Transplant 15(8):919–929. https://doi.org/10.1016/j.bbmt.2009.04.004

    Article  CAS  PubMed  Google Scholar 

  19. Pinana JL, Valcarcel D, Fernandez-Aviles F, Martino R, Rovira M, Barba P, Martinez C, Brunet S, Sureda A, Carreras E, Sierra J (2010) MTX or mycophenolate mofetil with CsA as GVHD prophylaxis after reduced-intensity conditioning PBSCT from HLA-identical siblings. Bone Marrow Transplant 45(9):1449–1456. https://doi.org/10.1038/bmt.2009.362

    Article  CAS  PubMed  Google Scholar 

  20. Hamilton BK, Rybicki L, Dean R, Majhail NS, Haddad H, Abounader D, Hanna R, Sobecks R, Duong H, Hill BT, Copelan E, Bolwell B, Kalaycio M (2015) Cyclosporine in combination with mycophenolate mofetil versus methotrexate for graft versus host disease prevention in myeloablative HLA-identical sibling donor allogeneic hematopoietic cell transplantation. Am J Hematol 90(2):144–148. https://doi.org/10.1002/ajh.23882

    Article  CAS  PubMed  Google Scholar 

  21. Maris MB, Niederwieser D, Sandmaier BM, Storer B, Stuart M, Maloney D, Petersdorf E, McSweeney P, Pulsipher M, Woolfrey A, Chauncey T, Agura E, Heimfeld S, Slattery J, Hegenbart U, Anasetti C, Blume K, Storb R (2003) HLA-matched unrelated donor hematopoietic cell transplantation after nonmyeloablative conditioning for patients with hematologic malignancies. Blood 102(6):2021–2030. https://doi.org/10.1182/blood-2003-02-0482

    Article  CAS  PubMed  Google Scholar 

  22. Maris MB, Sandmaier BM, Storer BE, Maloney DG, Shizuru JA, Agura E, Kliem C, Pulsipher M, Maziarz RT, McSweeney PA, Wade J, Langston AA, Chauncey TR, Bruno B, Blume KG, Storb R (2006) Unrelated donor granulocyte colony-stimulating factor-mobilized peripheral blood mononuclear cell transplantation after nonmyeloablative conditioning: the effect of postgrafting mycophenolate mofetil dosing. Biol Blood Marrow Transplant 12(4):454–465. https://doi.org/10.1016/j.bbmt.2005.12.030

    Article  CAS  PubMed  Google Scholar 

  23. Rodriguez R, Parker P, Nademanee A, Smith D, O’Donnell MR, Stein A, Snyder DS, Fung HC, Krishnan AY, Popplewell L, Cohen S, Somlo G, Angelopoulou M, Al-Kadhimi Z, Falk PM, Spielberger R, Kogut N, Sahebi F, Senitzer D, Slovak M, Schriber J, Forman SJ (2004) Cyclosporine and mycophenolate mofetil prophylaxis with fludarabine and melphalan conditioning for unrelated donor transplantation: a prospective study of 22 patients with hematologic malignancies. Bone Marrow Transplant 33(11):1123–1129. https://doi.org/10.1038/sj.bmt.1704493

    Article  CAS  PubMed  Google Scholar 

  24. Perez-Simon JA, Martino R, Caballero D, Valcarcel D, Rebollo N, de la Camara R, de Oteiza JP, Heras I, Calvo MV, Sierra J, San Miguel JF (2008) Reduced-intensity conditioning allogeneic transplantation from unrelated donors: evaluation of mycophenolate mofetil plus cyclosporin A as graft-versus-host disease prophylaxis. Biol Blood Marrow Transplant 14(6):664–671. https://doi.org/10.1016/j.bbmt.2008.03.007

    Article  CAS  PubMed  Google Scholar 

  25. Kharfan-Dabaja M, Mhaskar R, Reljic T, Pidala J, Perkins JB, Djulbegovic B, Kumar A (2014) Mycophenolate mofetil versus methotrexate for prevention of graft-versus-host disease in people receiving allogeneic hematopoietic stem cell transplantation. Cochrane Database Syst Rev (7):Cd010280. https://doi.org/10.1002/14651858.CD010280.pub2

  26. Iida M, Fukuda T, Ikegame K, Yoshihara S, Ogawa H, Taniguchi S, Takami A, Abe Y, Hino M, Etou T, Ueda Y, Yujiri T, Matsui T, Okamura A, Tanaka J, Atsuta Y, Kodera Y, Suzuki R (2011) Use of mycophenolate mofetil in patients received allogeneic hematopoietic stem cell transplantation in Japan. Int J Hematol 93(4):523–531. https://doi.org/10.1007/s12185-011-0817-8

    Article  CAS  PubMed  Google Scholar 

  27. Iida M, Fukuda T, Uchida N, Murata M, Aotsuka N, Minagawa K, Oohashi K, Fukushima K, Kondo T, Eto T, Miyamoto T, Morishima Y, Nagamura T, Atsuta Y, Suzuki R (2014) Mycophenolate mofetil use after unrelated hematopoietic stem cell transplantation for prophylaxis and treatment of graft-vs.-host disease in adult patients in Japan. Clin Transplant 28(9):980–989. https://doi.org/10.1111/ctr.12405

    Article  CAS  PubMed  Google Scholar 

  28. Okamura A, Yamamori M, Shimoyama M, Kawano Y, Kawano H, Kawamori Y, Nishikawa S, Minagawa K, Yakushi** K, Katayama Y, Sakaeda T, Hirai M, Matsui T (2008) Pharmacokinetics-based optimal dose-exploration of mycophenolate mofetil in allogeneic hematopoietic stem cell transplantation. Int J Hematol 88(1):104–110. https://doi.org/10.1007/s12185-008-0093-4

    Article  CAS  PubMed  Google Scholar 

  29. Okamura A, Shimoyama M, Ishii S, Wakahashi K, Asada N, Kawano H, Kawamori Y, Nishikawa S, Minagawa K, Katayama Y, Matsui T (2011) Delayed neutrophil engraftment in cord blood transplantation with intensive administration of mycophenolate mofetil for GVHD prophylaxis. Bone Marrow Transplant 46(1):148–149. https://doi.org/10.1038/bmt.2010.59

    Article  CAS  PubMed  Google Scholar 

  30. Wakahashi K, Yamamori M, Minagawa K, Ishii S, Nishikawa S, Shimoyama M, Kawano H, Kawano Y, Kawamori Y, Sada A, Matsui T, Katayama Y (2011) Pharmacokinetics-based optimal dose prediction of donor source-dependent response to mycophenolate mofetil in unrelated hematopoietic cell transplantation. Int J Hematol 94(2):193–202. https://doi.org/10.1007/s12185-011-0888-6

    Article  CAS  PubMed  Google Scholar 

  31. Nishikawa S, Okamura A, Yamamori M, Minagawa K, Kawamori Y, Kawano Y, Kawano H, Ono K, Katayama Y, Shimoyama M, Matsui T (2009) Extended mycophenolate mofetil administration beyond day 30 in allogeneic hematopoietic stem cell transplantation as preemptive therapy for severe graft-versus-host disease. Transplant Proc 41(9):3873–3876. https://doi.org/10.1016/j.transproceed.2009.06.231

    Article  CAS  PubMed  Google Scholar 

  32. Przepiorka D, Weisdorf D, Martin P, Klingemann HG, Beatty P, Hows J, Thomas ED (1995) 1994 Consensus Conference on Acute GVHD Grading. Bone Marrow Transplant 15(6):825–828

    CAS  PubMed  Google Scholar 

  33. Kanda Y (2013) Investigation of the freely available easy-to-use software ‘EZR’ for medical statistics. Bone Marrow Transplant 48(3):452–458. https://doi.org/10.1038/bmt.2012.244

    Article  CAS  PubMed  Google Scholar 

  34. van Hest RM, Doorduijn JK, de Winter BC, Cornelissen JJ, Vulto AG, Oellerich M, Lowenberg B, Mathot RA, Armstrong VW, van Gelder T (2007) Pharmacokinetics of mycophenolate mofetil in hematopoietic stem cell transplant recipients. Ther Drug Monit 29(3):353–360. https://doi.org/10.1097/FTD.0b013e31805d8816

    Article  PubMed  Google Scholar 

  35. Ng J, Rogosheske J, Barker J, Weisdorf D, Jacobson PA (2006) A limited sampling model for estimation of total and unbound mycophenolic acid (MPA) area under the curve (AUC) in hematopoietic cell transplantation (HCT). Ther Drug Monit 28(3):394–401. https://doi.org/10.1097/01.ftd.0000211821.73231.8a

    Article  CAS  PubMed  Google Scholar 

  36. Bhatia M, Militano O, ** Z, Figurski M, Shaw L, Moore V, Morris E, Tallamy B, van deVen C, Ayello J, Baxter-Lowe L, Satwani P, George D, Bradley MB, Garvin J, Cairo MS (2010) An age-dependent pharmacokinetic study of intravenous and oral mycophenolate mofetil in combination with tacrolimus for GVHD prophylaxis in pediatric allogeneic stem cell transplantation recipients. Biol Blood Marrow Transplant 16(3):333–343. https://doi.org/10.1016/j.bbmt.2009.10.007

    Article  CAS  PubMed  Google Scholar 

  37. Morishima Y, Kawase T, Malkki M, Morishima S, Spellman S, Kashiwase K, Kato S, Cesbron A, Tiercy JM, Senitzer D, Velardi A, Petersdorf EW (2013) Significance of ethnicity in the risk of acute graft-versus-host disease and leukemia relapse after unrelated donor hematopoietic stem cell transplantation. Biol Blood Marrow Transplant 19(8):1197–1203. https://doi.org/10.1016/j.bbmt.2013.05.020

    Article  PubMed  PubMed Central  Google Scholar 

  38. Jacobson P, Rogosheske J, Barker JN, Green K, Ng J, Weisdorf D, Tan Y, Long J, Remmel R, Sawchuk R, McGlave P (2005) Relationship of mycophenolic acid exposure to clinical outcome after hematopoietic cell transplantation. Clin Pharmacol Ther 78(5):486–500. https://doi.org/10.1016/j.clpt.2005.08.009

    Article  CAS  PubMed  Google Scholar 

  39. Jacobson P, El-Massah SF, Rogosheske J, Kerr A, Long-Boyle J, DeFor T, Jennissen C, Brunstein C, Wagner J, Tomblyn M, Weisdorf D (2009) Comparison of two mycophenolate mofetil dosing regimens after hematopoietic cell transplantation. Bone Marrow Transplant 44(2):113–120. https://doi.org/10.1038/bmt.2008.428

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  40. Nakane T, Nakamae H, Koh H, Nakamae M, Hayashi Y, Nishimoto M, Yoshimura T, Inoue E, Inoue A, Aimoto R, Aimoto M, Terada Y, Koh KR, Yamane T, Hino M (2011) Reduced-intensity conditioning by fludarabine/busulfan without additional irradiation or T-cell depletion leads to low non-relapse mortality in unrelated bone marrow transplantation. Int J Hematol 93(4):509–516. https://doi.org/10.1007/s12185-011-0805-z

    Article  PubMed  Google Scholar 

  41. Kuwatsuka Y, Kohno A, Terakura S, Saito S, Shimada K, Yasuda T, Inamoto Y, Miyamura K, Sawa M, Murata M, Karasuno T, Taniguchi S, Nagafuji K, Atsuta Y, Suzuki R, Fukumoto M, Naoe T, Morishita Y (2012) Phase II study of dose-modified busulfan by real-time targeting in allogeneic hematopoietic stem cell transplantation for myeloid malignancy. Cancer Sci 103(9):1688–1694. https://doi.org/10.1111/j.1349-7006.2012.02342.x

    Article  CAS  PubMed  Google Scholar 

  42. Fuji S, Ueno N, Hiramoto N, Asakura Y, Yakushi** K, Kamiyama Y, Kurosawa S, Kim SW, Heike Y, Yamashita T, Fukuda T (2013) Reduced-intensity conditioning regimen with low-dose ATG-F for unrelated bone marrow transplant is associated with lower non-relapse mortality than a regimen with low-dose TBI: a single-center retrospective analysis of 103 cases. Int J Hematol 98(5):608–614. https://doi.org/10.1007/s12185-013-1449-y

    Article  CAS  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Division of Medical Oncology/Hematology, Department of Medicine, Kobe University Graduate School of Medicine, Kobe, Hyogo, Japan

    Keiji Kurata & Hironobu Minami

  2. Department of Medical Oncology and Hematology, Kobe University Hospital, Kobe, Hyogo, Japan

    Keiji Kurata, Kimikazu Yakushi**, Atsuo Okamura, Hiroya Ichikawa, Rina Sakai, Yu Mizutani, Seiji Kakiuchi, Yoshiharu Miyata, Akihito Kitao, Hiroshi Matsuoka & Hironobu Minami

  3. Department of Hematology/Oncology, Kakogawa Central City Hospital, Kakogawa, Hyogo, Japan

    Atsuo Okamura

  4. Department of Clinical Pharmacy, School of Pharmacy and Pharmaceutical Sciences, Mukogawa Women’s University, Nishinomiya, Hyogo, Japan

    Motohiro Yamamori

  5. Department of Transfusion Medicine and Cell Therapy, Kobe University Hospital, Kobe, Hyogo, Japan

    Shinichiro Kawamoto

  6. Department of Hematology, Hyogo Cancer Center, Akashi, Hyogo, Japan

    Tohru Murayama

Authors
  1. Keiji Kurata
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Kimikazu Yakushi**
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Atsuo Okamura
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Motohiro Yamamori
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Hiroya Ichikawa
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Rina Sakai
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. Yu Mizutani
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. Seiji Kakiuchi
    View author publications

    You can also search for this author in PubMed Google Scholar

  9. Yoshiharu Miyata
    View author publications

    You can also search for this author in PubMed Google Scholar

  10. Akihito Kitao
    View author publications

    You can also search for this author in PubMed Google Scholar

  11. Shinichiro Kawamoto
    View author publications

    You can also search for this author in PubMed Google Scholar

  12. Hiroshi Matsuoka
    View author publications

    You can also search for this author in PubMed Google Scholar

  13. Tohru Murayama
    View author publications

    You can also search for this author in PubMed Google Scholar

  14. Hironobu Minami
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Hironobu Minami.

Ethics declarations

Conflict of interest

All authors declared that they have no potential conflict of interest.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Kurata, K., Yakushi**, K., Okamura, A. et al. Pharmacokinetics of intravenous mycophenolate mofetil in allogeneic hematopoietic stem cell-transplanted Japanese patients. Cancer Chemother Pharmacol 81, 839–846 (2018). https://doi.org/10.1007/s00280-018-3550-7

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00280-018-3550-7

Keywords

Search

Navigation